Glutamine transporter SLC1A5 inhibits autophagy-mediated CD276 degradation to promote esophageal cancer progression

Key Points

• The research aims to understand how SLC1A5 affects CD276 stability and esophageal cancer progression.
• Investigated the role of SLC1A5 in regulating CD276 stability
• Analyzed the impact of ROS-autophagy signaling on CD276 degradation
• Explored potential therapeutic strategies targeting glutamine metabolism for ESCC
• SLC1A5 was found to enhance CD276 stability
• Inhibition of ROS-autophagy signaling was linked to increased CD276 levels
• Suggests targeting glutamine metabolism could improve CD276 degradation and combat ESCC progression